Matinas Biopharma Holdings Inc

ASE:MTNB  
1.10
-0.06 (-5.17%)
Regulatory, Earnings Announcements

Matinas Reports Positive Data In Ongoing EnACT Trial of MAT2203 For Treatment Of Cryptococcal Meningitis

Published: 09/13/2021 11:44 GMT
Matinas Biopharma Holdings Inc (MTNB) - Matinas Biopharma Announces Positive Data in Ongoing Enact Trial of Mat2203 (oral Amphotericin B) for Treatment of Cryptococcal Meningitis, Exceeding Prespecified Primary Endpoint Threshold.
Matinas Biopharma Holdings Inc - Step-down Therapy With Mat2203 Achieved Effective Clearance of Fungal Organisms.
Matinas Biopharma Holdings Inc - Mean Early Fungicidal Activity (efa) Was 0.38, Exceeding Prespecified Primary Endpoint Threshold Target of >0.20.
Matinas Biopharma Holdings Inc - Overall Survival Was >95% in 40 Patients Receiving Mat2203 in Cohort 2.
Matinas Biopharma Holdings Inc - All 39 Patients Completing Induction With Mat2203 Achieved Sterility.
Matinas Biopharma Holdings - Preparing to Engage With FDA to Review Enact Data As Supportive of Potential Early Approval of Mat2203 As Step-down Therapy.
Revenue is expected to be $1.53 Million
Adjusted EPS is expected to be -$0.02

Next Quarter Revenue Guidance is expected to be $0.34 Million
Next Quarter EPS Guidance is expected to be -$0.03

More details on our Analysts Page.